Hutton, B. & Fergusson, D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 80, 1461-1468

University of Ottawa, Ottawa, Ontario, Canada
American Journal of Clinical Nutrition (Impact Factor: 6.77). 01/2005; 80(6):1461-8.
Source: PubMed


Obesity is a growing health concern in Canada and the United States, and pharmacologic therapies such as orlistat are being more commonly prescribed to assist with weight loss.
Our goal was to assess the efficacy and safety of orlistat compared with either placebo or an active control with regard to weight loss and serum lipid changes in overweight patients.
We performed a systematic literature search of MEDLINE (1966 through December 2003) and the Cochrane Central Register of Controlled Trials. Relevant trials and reviews were searched by hand. Randomized trials comparing orlistat and a control and reporting changes in weight loss, serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol, LDL:HDL, and triacylglycerols), or both in overweight and obese patients [body mass index (in kg/m2) > or =25] were included.
Twenty-eight randomized trials met our inclusion criteria. Seventeen studies including 10,041 patients compared 3 x 120 mg orlistat/d with placebo or an inactive control along with a hypocaloric diet over a 1-y period. Relative risks (RRs) associated with clinically significant weight losses of 5% and 10% were 1.74 (95% CI: 1.57, 1.91) and 1.96 (1.74, 2.21), both favoring orlistat. Improvement in total cholesterol, LDL cholesterol, HDL cholesterol, and LDL:HDL were also greater with orlistat. Gastrointestinal events were more common with orlistat than with placebo [RR: 1.46 (1.37, 1.55)].
Our findings suggest that 3 x 120 mg orlistat/d is effective for improving both weight loss and serum lipid profiles in obese patients at low and high cardiovascular disease risk and in obese patients with type 2 diabetes.

Download full-text


Available from: Brian Hutton, Jan 04, 2014
  • Source
    • "Currently, two approved drugs are available on the market, orlistat and sibutramine [26] [30] [31]. Orlistat (Xenical) reduces intestinal fat absorption through inhibition of pancreatic lipase [32] [33] [34] [35]; while sibutramine (Reductil) is an anorectic, or appetite suppressant [36] [37] [38]. Both drugs have hazardous sideeffects , including increased blood pressure, dry mouth, constipation, headache, and insomnia [35] [39] [40] [41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is a global epidemic and one of the major health burdens of modern times. The prevalence of obesity is increasing worldwide; it constitutes a serious problem in developed as well as developing countries. Beside adults, the number of obese teenagers and children in particular has dramatically increased. Obesity is characterized by accumulation of excess fat in adipose tissues in an extent to produce adverse effects on health, leading to a reduction in life expectancy and/or a raise in health hazards. People are classified as overweight (pre-obese) and obese on the basis of the Body Mass Index (BMI), crude measure which compares weight to height. Obesity is usually associated with and can lead to many disease conditions, mainly type-2 diabetes, cardiac diseases, hypertension, sleep apnea, cerebrovascular incidents, osteoarthritis and certain types of cancers. The tremendously increasing number of reviews on the subject of obesity obviously reflects the amount of investigations currently dedicated to this field. The core of obesity treatment is dieting and physical exercise. The consumption of energy-dense food is reduced versus an increase in that of dietary fibers. Conventional medication relies mainly on drugs which either reduce appetite or inhibit fat absorption. However, drug treatment of obesity despite short-term benefits, is often associated with undesirable harmful side effects, rebound weight gain after discontinuation of drug intake, and the incidence of drug abuse. If diet, exercise and pharmacological therapy are ineffective; surgical intervention may be useful. The anti-obesity potential of natural products if accurately explored might provide an excellent alternative strategy for the scientifically-based development of safe and effective drugs. Especially that, they are actually widespread for this purpose as nutritional supplements. OTC anti-obesity natural products are mostly complex in terms of chemical composition and may exert a variety of pharmacological actions leading to weight loss. These include: inhibition of lipases activity, suppression of appetite, stimulation of energy expenditure, inhibition of adipocyte differentiation and regulation of lipid metabolism. A variety of natural products, including crude extracts and isolated compounds induce body weight reduction and prevent diet-induced obesity. Examples of these constituents are polyphenols, triterpenoidal and steroidal saponins, pregnane glycosides, alkaloids, abietane diterpenes and carotenoids amongst others. In addition, a number of lipase inhibitors are obtained from microbial sources.
    Full-text · Chapter · Sep 2014
  • Source
    • "Furthermore, inhibition of fat absorption should also have a beneficial effect on lipid metabolism and cardiovascular health. Indeed, it has been shown that reducing fat absorption with Xenical has a direct effect on lipid profile in the blood and a beneficial long term effect on the cardiovascular system [27], [28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity research focuses essentially on gene targets associated with the obese phenotype. None of these targets have yet provided a viable drug therapy. Focusing instead on genes that are involved in energy absorption and that are associated with a "human starvation phenotype", we have identified enteropeptidase (EP), a gene associated with congenital enteropeptidase deficiency, as a novel target for obesity treatment. The advantages of this target are that the gene is expressed exclusively in the brush border of the intestine; it is peripheral and not redundant. Potent and selective EP inhibitors were designed around a boroarginine or borolysine motif. Oral administration of these compounds to mice restricted the bioavailability of dietary energy, and in a long-term treatment it significantly diminished the rate of increase in body weight, despite ad libitum food intake. No adverse reactions of the type seen with lipase inhibitors, such as diarrhea or steatorrhea, were observed. This validates EP as a novel, druggable target for obesity treatment. In vivo testing of novel boroarginine or borolysine-based EP inhibitors validates a novel approach to the treatment of obesity.
    Full-text · Article · Nov 2012 · PLoS ONE
  • Source
    • "The only licensed pharmacological treatment for obesity in the UK is orlistat, an intestinal lipase inhibitor. This produces modest weight loss (in a systematic review of randomized clinical trials, 60% of patients on orlistat achieved >5% weight loss after 1 year of treatment).6 Furthermore, as a consequence of its mechanism of action, orlistat often leads to unacceptable gastrointestinal side effects when fat is consumed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The global obesity epidemic has resulted in significant morbidity and mortality. However, the medical treatment of obesity is limited. Gastric bypass is an effective surgical treatment but carries significant perioperative risks. The gut hormones, peptide tyrosine tyrosine (PYY) and glucagon-like peptide 1 (GLP-1), are elevated following gastric bypass and have been shown to reduce food intake. They may provide new therapeutic targets. This review article provides an overview of the central control of food intake and the role of PYY and GLP-1 in appetite control. Key translational animal and human studies are reviewed.
    Full-text · Article · Jan 2012 · Gut and liver
Show more